Semaglutide shows promise in reducing alcohol cravings and consumption. Could it be a future treatment for AUD?

Novo Nordisk is providing direct-to-patient delivery of Wegovy (semaglutide) through the NovoCare Pharmacy program.

(HealthDay News) — Low-dose semaglutide seems to reduce craving and certain drinking outcomes in alcohol use disorder (AUD), according to a study published online Feb. 12 in JAMA Psychiatry.

New Delhi: Noting that post-marketing safety data in Indian patients is not presented, the Subject Expert Committee (SEC) ...

ASC47, an adipose-targeted muscle-preserving weight loss drug candidate for the treatment of obesity, demonstrated a half-life of up to 26 days and 40 days, respectively, in Phase Ib single ...

In clinical trials supported by Novo Nordisk, gallstones were reported in 1.5 percent of participants taking a 0.5 mg dose of semaglutide and 0.4 percent of those taking the 1 mg dose. No cases of ...

The treatment group received 0.5 mg of semaglutide per week. All participants were between 21 and 65 years of age. Women consuming more than seven and men consuming more than fourteen alcoholic ...

The researchers found that low-dose semaglutide (0.25 mg/week for 4 weeks, 0.5 mg/week for 4 weeks, and 1 mg for one week) reduced the amount of alcohol consumed during a posttreatment laboratory ...

NovoCare Pharmacy will provide all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying patients ...

The 40-week SUSTAIN 7 trial investigated the efficacy and safety of 0.5 mg semaglutide compared with 0.75 dulaglutide and 1.0 mg semaglutide compared with 1.5 mg dulaglutide, when added to metformin.

Ascletis Pharma Inc. (ASCLF.PK) announced promising pharmacokinetic and weight loss data from its ASC47 Phase Ib single subcutaneous injection studies conducted in Australia.